european trial on reduction of cardiac events with perindopril in stable coronary artery disease l.
Download
Skip this Video
Loading SlideShow in 5 Seconds..
European trial on reduction of cardiac events with perindopril in stable coronary artery disease PowerPoint Presentation
Download Presentation
European trial on reduction of cardiac events with perindopril in stable coronary artery disease

Loading in 2 Seconds...

play fullscreen
1 / 4

European trial on reduction of cardiac events with perindopril in stable coronary artery disease - PowerPoint PPT Presentation


  • 260 Views
  • Uploaded on

EUROPA Trial. European trial on reduction of cardiac events with perindopril in stable coronary artery disease . Presented at European Society of Cardiology 2003. EUROPA Trial. 12,218 low-risk patients with stable coronary artery disease Randomized, double-blind, placebo-controlled .

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'European trial on reduction of cardiac events with perindopril in stable coronary artery disease' - Ava


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
european trial on reduction of cardiac events with perindopril in stable coronary artery disease

EUROPA Trial

European trial on reduction of cardiac events with perindopril in stable coronary artery disease

Presented at

European Society of Cardiology 2003

europa trial
EUROPA Trial

12,218 low-risk patients with stable coronary artery disease

Randomized, double-blind, placebo-controlled

  • Perindopril
  • 8 mg/day
  • n=6,110
  • Placebo
  • n= 6,108
  • Endpoints (follow-up mean 3.4 years):
    • Primary – Composite of CV mortality, nonfatal MI, and cardiac arrest
    • Secondary – Composite of total death, nonfatal MI, and cardiac arrest; heart failure; revascularization (PCI/CABG); and stroke

European Society of Cardiology 2003

europa trial3
EUROPA Trial

CV Mortality

p=0.107

CV death/non-fatal MI/

cardiac arrest

p=0.0003

European Society of Cardiology 2003

europa trial4
EUROPA Trial
  • Among patients with stable coronary artery disease, treatment with the ACE-I perindopril was associated with a reduction in the primary endpoint of cardiovascular mortality, non-fatal MI, and cardiac arrest compared with placebo
  • ACE inhibitors have previously been shown to be effective in other patient populations, including heart failure, left ventricular dysfunction, and high-risk coronary artery disease patients
  • The present trial is the largest to show a benefit in stable, low-risk CAD patients